newest glp-1 drug Novo's Wegovy becomes first approved for MASH GLP-1 Weight Loss Drugs May

Fax your request to 1-855-330-1716, or

While some experience noticeable shedding, others report no changes in their hair

Circulation 129(5):587597 van Bommel EJ, Muskiet MH, van Baar MJ, Tonneijck L, Smits MM, Emanuel AL et al (2019) The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

The smart scale is unique in our lineup and tracks lean mass, which matters because women and older adults on semaglutide face higher muscle-loss risk per ENDO 2025

Closed Captioning Feedback Where to Watch Be Smart Be Smart is available to stream on pbs.org and the PBS app

Economic, Accessibility, and Health Equity Considerations The economic considerations surrounding the use of Ozempic and similar GLP-1 receptor agonists (such as Wegovy which uses the same active ingredient), encompass numerous aspects of the economy and healthcare system